Stage2 Ventures, L.P.Stage2... Net Worth

Insiders trading at Tabula Rasa HealthCare Inc

Over the last 8 years, insiders at Tabula Rasa HealthCare Inc have traded over $245,667,405 worth of Tabula Rasa HealthCare Inc stock and bought 1,486,398 units worth $7,620,320 . The most active insiders traders include Calvin H Knowlton, Orsula V Knowlton oraz Capital Management, L.P.Ic .... On average, Tabula Rasa HealthCare Inc executives and independent directors trade stock every 8 days with the average trade being worth of $441,116. The most recent stock trade was executed by Michael Greenhalgh on 28 June 2023, trading 25,000 units of TRHC stock currently worth $77,750.

What does Tabula Rasa HealthCare Inc do?

the tabula rasa healthcare family of companies provide new beginnings for our clients, through innovative service models and fresh approaches to healthcare technology. our leaders understand that to maximize patient experiences and outcomes, they must help providers to balance efficiency and scalability with safety and individualization of care.

Tabula Rasa HealthCare Inc executives and stock owners

Tabula Rasa HealthCare Inc executives and other stock owners filed with the SEC include:

• Calvin Knowlton,
  Chairman of the Board, Chief Executive Officer, Co-Founder
• Orsula Knowlton,
  President, Co-Founder, Chief Marketing Officer & New Business Development Officer, Director
• Brian Adams,
  Chief Financial Officer
• Pamela Schweitzer,
  Independent Director
• Dr. Calvin H. Knowlton BSc Pharm, MDiv, Ph.D.,
  Co-Founder, Chairman & CEO
• A. Gordon Tunstall,
  Lead Independent Director
• Dr. Orsula Voltis Knowlton BScPharm, M.B.A., MBA, Pharm.D., PharmD,
  Co-Founder, Pres, Chief Marketing & New Bus. Devel. Officer and Director
• Michael Greenhalgh,
  Chief Operating Officer
• Michael Purcell,
  Independent Director
• Samira Beckwith,
  Independent Director
• Dennis Helling,
  Independent Director
• Jan Berger,
  Independent Director
• Kathrine O'Brien,
  Independent Director
• Frank Sparacino,
  IR Contact Officer
• Jeffrey DiFrancesco,
  Chief Product Officer
• Bob Sullivan,
  Chief Technology Officer
• Steve Lemak,
  Senior Vice President - IT Infrastructure, CareVention HealthCare Division
• Michael Greenhalgh,
  Co-Founder, Chief Operating Officer
• Frank Sparacino C.F.A., CPA,
  Sr. VP of Investor Relations & Corp. Devel.
• Phillip W. Heath MS,
  Chief Admin. Officer
• Dr. Jacques Turgeon B.Pharm., Ph.D.,
  Chief Scientific Officer & CEO of TRHC Precision Pharmacotherapy, R&D Institute
• Joseph J. Filippoli,
  Chief Information Officer
• Bob Sullivan M.S.,
  Chief Technology Officer
• Andrea Carolan Speers M.S.,
  Corp. Controller & Chief Accounting Officer
• Bruce Luehrs,
  Director
• Venture Partners Iii, Llcra...,
  
• Eric R Arnson,
  10% owner
• Growth Fund 1 Q Lpbressner ...,
  
• Daniel C Lubin,
  Director
• Michael J Gausling,
  10% owner
• Glen R Bressner,
  Director
• Growth Fund 1 A Lpbressner ...,
  
• Joann M. Durham,
  10% owner
• John R. Durham,
  10% owner
• Growth Fund 1 A Lp Originat...,
  
• Stage2 Ventures, L.P.Stage2...,
  
• Growth Fund 1 Q Lp Originat...,
  
• Michael Anthony Bruno,
  CHIEF ACCOUNTING OFFICER
• Ronald Paul Mitchell,
  
• Thomas Cancro,
  CHIEF FINANCIAL OFFICER
• Richard W. Ii Rew,
  CHIEF LEGAL OFFICER, SECRETARY
• Jonathan David Schwartz,
  
• Capital Management, L.P.Ic ...,
  
• Capital Management, L.P.Ic ...,
  
• Capital Management, L.P.Ind...,